VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASTRO 2022 | Results of Phase II trial comparing TACE and SBRT for hepatocellular carcinoma

Alejandra Mendez Romero, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses results from a randomized Phase II multicenter study (NCT02470533) which compared the use of transarterial chemoembolization (TACE) with drug-eluting beads to the use of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). The target enrollment of the study was 100 patients, but the trial was terminated early due to a low accrual of 30 patients. 16 patients were included in the TACE arm and 14 patients in the SBRT arm. The time to progression was 12 months in the TACE arm and 18.8 months in the SBRT arms, with this difference not being significant. The study also looked at local control, based on intention to treat. The median survival in the TACE arm was 36.8 months compared to 44.1 months after SBRT, which was not a significant difference. Response rates were good in both arms, with around 80% response in the TACE arm and 90% response in SBRT arm. Dr Romero also discusses toxicity results and quality of life implications. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter